A
Allan J. Pantuck
Researcher at University of California, Los Angeles
Publications - 373
Citations - 23781
Allan J. Pantuck is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Renal cell carcinoma & Nephrectomy. The author has an hindex of 74, co-authored 362 publications receiving 21728 citations. Previous affiliations of Allan J. Pantuck include Ronald Reagan UCLA Medical Center & UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more
TL;DR: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Journal ArticleDOI
The changing natural history of renal cell carcinoma
TL;DR: The understanding of the natural history of renal cell carcinoma, the role of nephrectomy, the benefits of immunotherapy and the possibilities of new technologies are evolving and being integrated with advances in classification and staging.
Journal Article
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy
Matthew H. T. Bui,David Seligson,Ken Ryu Han,Allan J. Pantuck,Frederick J. Dorey,Yunda Huang,Steve Horvath,Bradley C. Leibovich,Shefali Chopra,Shu Yuan Liao,Eric J. Stanbridge,Michael I. Lerman,Aarno Palotie,Robert A. Figlin,Arie S. Belldegrun +14 more
TL;DR: Lower CAIX levels are independently associated with poor survival in advanced RCC, which reflects significant changes in tumor biology, which should be used to predict clinical outcome and identify high-risk patients in need for adjuvant immunotherapy and CAIX-targeted therapies.
Journal ArticleDOI
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Amnon Zisman,Allan J. Pantuck,Fredrick Dorey,Jonathan W. Said,Oleg Shvarts,Deanna Quintana,Barbara J. Gitlitz,Jean B. deKernion,Robert A. Figlin,Arie S. Belldegrun +9 more
TL;DR: The data suggests that UISS is an important prognostic tool for counseling patients with various stages of kidney cancer and is superior to stage alone in differentiating patients' survival.
Journal ArticleDOI
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
Jean Jacques Patard,Emmanuelle Leray,Nathalie Rioux-Leclercq,Luca Cindolo,Vincenzo Ficarra,Amnon Zisman,Alexandre de la Taille,Jacques Tostain,Walter Artibani,Claude C. Abbou,Bernard Lobel,Francois Guille,Chopin D,Peter F.A. Mulders,Christopher G. Wood,David A. Swanson,Robert A. Figlin,Arie S. Belldegrun,Allan J. Pantuck +18 more
TL;DR: In univariate analysis, a trend toward a better survival was observed when clear cell, papillary, and chromophobe histologies were considered and the Kaplan-Meier method and Cox model was used.